Risk Factors for the Development of a Progressive Course of Atopic Dermatitis in Children and Adolescents
https://doi.org/10.31550/1727-2378-2022-21-7-41-44
Abstract
Study Objective: To determine the risk factors for the development of a progressive course of atopic dermatitis (AD) in children and adolescents.
Study Design: Observational prospective cross-sectional study.
Materials and Methods. The study enrolled 89 outpatients with AD aged 2 months — 17 years. The diagnosis was verified based on Hanifin and Rajkа criteria (1980); skin disorders were assessed via SCORAD followed by statistical analysis. Family history, breastfeeding duration and symptoms manifestation were assessed.
Study Results. Based on our results, compared to children with erythemato-squamous plaques with lichenization AD (ESPL) and lichenoid AD (L), children with erythemato-squamous plaques of AD (ESP) predominated (ESP vs. ESPL vs. L: 44 (50%) vs. 28 (31%) vs. 17 (19%) respectively (p < 0.05). Progressive AD was noticed in more than 50% (p < 0.05). SCORAD index was maximal in lichenoid AD (p < 0.05). Progressive AD is frequently accompanied with genetic predisposition on the mother’s side as well as early AD manifestation and shorter breastfeeding. Prolonged course of the disease influences the risks for lichenoid forms.
Conclusion. Risks for progressive course of AD is higher in children with genetic predisposition on the mother’s side, duration of breastfeeding with regard to early AD manifestation. Basically, clinical symptoms of the atopic march were related to seasonal allergic rhinitis, less often with asthma.
About the Authors
V. A. Soboleva
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Scientific Institution “Research Institute of Vaccines and Serums them. I.I. Mechnikov”
Russian Federation
Russian Federation
19 Bolshaya Pirogovskaya Str., build. 1, Moscow, 119991
5a Maly Kazeny Lane, Moscow, 105064
A. V. Kudryavtseva
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Scientific Institution “Research Institute of Vaccines and Serums them. I.I. Mechnikov”
Russian Federation
Russian Federation
19 Bolshaya Pirogovskaya Str., build. 1, Moscow, 119991
5a Maly Kazeny Lane, Moscow, 105064
O. A. Svitich
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Scientific Institution “Research Institute of Vaccines and Serums them. I.I. Mechnikov”
Russian Federation
Russian Federation
19 Bolshaya Pirogovskaya Str., build. 1, Moscow, 119991
5a Maly Kazeny Lane, Moscow, 105064
N. A. Geppe
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
19 Bolshaya Pirogovskaya Str., build. 1, Moscow, 119991
References
1. Honda T., Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. J. Allergy Clin. Immunol. 2020; 145(4): 1136–7. DOI: 10.1016/j.jaci.2020.02.008
2. Mohn C.H., Blix H.S., Halvorsen J.A., Nafstad P. et al. Incidence trends of atopic dermatitis in infancy and early childhood in a nationwide prescription registry study in Norway. JAMA Netw. Open. 2018; 1(7): e184145. DOI: 10.1001/jamanetworkopen.2018.4145
3. Silverberg J.I., Nelson D.B., Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J. Dermatol. Treat. 2016; 27(6): 568–76. DOI: 10.1080/09546634.2016.1174765
4. Eichenfield L.F., Luger T., Papp K., Silverberg J.I. et al. Topical agents for the treatment of atopic dermatitis. J. Drugs Dermatol. 2020; 19(1): 50–64. DOI: 10.36849/JDD.2020.4508
5. Fishbein A.B., Silverberg J.I., Wilson E.J., Ong P.Y. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J. Allergy Clin. Immunol. In Practice. 2020; 8(1): 91–101. DOI: 10.1016/j.jaip.2019.06.044
6. Kim Y.J., Yun S.J., Lee J.B., Kim S. J. et al. Four years prospective study of natural history of atopic dermatitis aged 7~8 years at an individual level: a community-based survey by dermatologists' skin examination in childhood. Ann. Dermatol. 2016; 28(6): 684–9. DOI: 10.5021/ad.2016.28.6.684
7. Moyle M., Cevikbas F., Harden J.L., Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches. Experim. Dermatol. 2019; 28(7): 756 68. DOI: 10.1111/exd.13911
8. Ratchataswan T., Banzon T.M., Thyssen J.P., Weidinger S. et al. Biologics for treatment of atopic dermatitis: current status and future prospect. J. Allergy Clin. Immunol. In Practice, 2021; 9(3): 1053–65. DOI: 10.1016/j. jaip.2020.11.034
9. Diluvio L., Dattola A., Cannizzaro M.V., Franceschini C. et al. Clinical and confocal evaluation of avenanthramides-based daily cleansing and emollient cream in pediatric population affected by atopic dermatitis and xerosis. G. Ital. Dermatol. Venereol. 2019; 154(1): 32–6. DOI: 10.23736/S0392-0488.18.06002-9
10. Soeberdt M., Kilic A., Abels C. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur. J. Pharmacol. 2020; 881: 173242. DOI: 10.1016/j.ejphar.2020.173242
11. Czarnowicki T., He H., Krueger J.G., Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J. Allergy Clin. Immunol. 2019; 143(1): 1–11. DOI: 10.1016/j.jaci.2018.10.032
12. Smieszek S.P., Welsh S., Xiao C., Wang J. et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci. Rep. 2020; 10(1): 2721. DOI: 10.1038/s41598-020-59627-7
13. Henriksen L., Simonsen J., Haerskjold A., Linder M. et al. Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in Danish and Swedish children. J. Allergy Clin. Immunol. 2017; 136(2): 360–6.e2. DOI: 10.1016/j.jaci.2015.02.003
14. Petriashvili M., Jorjoliani L. The peculiarities of clinical course of atopic dermatitis and the comorbid conditions in early infancy. Georgian Med. News. 2020; 298: 53–7.
15. Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S. et al. Consensus based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J. Eur. Acad. Dermatol. Venereol. 2018; 32(5): 657–82. DOI: 10.1111/jdv.14891
16. Johansson S.G., Hourihane J.O., Bousquet J., Bruijnzeel-Koomen C. et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001; 56(9): 813–24. DOI: 10.1034/j.1398-9995.2001.t01-1-00001.x
17. Johansson S.G., Bieber T., Dahl R., Friedmann P.S. et al Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 2004; 113(5): 832–6. DOI: 10.1016/j.jaci.2003.12.591
18. Cury Martins J., Martins C., Aoki V., Gois A.F. et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst. Rev. 2015; 2015(7): CD009864. DOI: 10.1002/14651858.CD009864.pub2
19. Tran M.M., Lefebvre D.L., Dharma C., Dai D. et al. Predicting the atopic march: results from the Canadian healthy infant longitudinal development study. J. Allergy Clin. Immunol. 2018; 141(2): 601–7.e8. DOI: 10.1016/j.jaci.2017.08.024
20. Gupta J., Margolis D.J. Filaggrin gene mutations with special reference to atopic dermatitis. Curr. Treat. Options Allergy. 2020; 7(3): 403–13. DOI: 10.1007/s40521-020-00271-x
21. Kudryavtseva A.V., Morozova O.A., Savvina Yu.A. The staphylococcal infection of skin lesions in children with atopic dermatitis. Allergology and Immunology in Pediatrics. 2013; 3(34): 23–7. (in Russian)
22. Butaye P., Argudín M.A., Smith T.C. Livestock-associated MRSA and its current evolution. Curr. Clin. Microbiol. Rep. 2016; 3: 19–31.
23. Kudryavtseva A.V., Katosova L.K., Balabolkin I.I., Aseeva V.G. Role of Staphylococcus aureus in pediatric atopic dermatitis. Pediatrics. Journal named after G.N. Speransky. 2003; 82(6): 32–6. (in Russian)
24. Paller A.S., Kong H.H., Seed P., Naik S. et al. The microbiome in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2019; 143(1): 26–35. DOI: 10.1016/j.jaci.2
Review
For citations:
Soboleva V.A., Kudryavtseva A.V., Svitich O.A., Geppe N.A. Risk Factors for the Development of a Progressive Course of Atopic Dermatitis in Children and Adolescents. Title. 2022;21(7):41-44. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-7-41-44
Views:
12
Email this article 